GlaxoSmithKline's Andrew Witty
Andrew Witty - GlaxoSmithKline
Total Compensation: $2.68M
Details: Witty has spent his entire career at GSK. In 2007, the industy vet's loyalty was rewarded when he was promoted from head of the European pharma unit to CEO following Dr. Jean-Pierre Garnier's retirement. The CEO beat out a number of other company veterans vying for the spot, including Chris Viehbacher--who later left to head Sanofi-Aventis. Witty officially took the reigns in May of 2008 and for just 6 months at the helm, he was awarded £1.78 million--or $2.68 million. At the time of his succession, Witty's base salary was set at $1.28 million; he received just over $1 million, plus a $1.5 million bonus.
GSK News:
GSK chief elaborates on biotech strategy
NICE snubs Glaxo's pay-for-performance plan
GlaxoSmithKline to axe 850 jobs in R&D
GSK to cut 1,800 U.S. pharma reps
GSK's Witty opts out of generics market
Witty: Diversifying and derisking GSK
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
